SCHEMBL922332

SCHEMBL922332

O=S(=O)(O)OS(=O)(=O)OCCO

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750419 0.98
SCHEMBL30541875 0.87 CA2 (0.35) CA2TSHR
SCHEMBL920407 0.86 CA1 (0.32) CA2TSHR
SCHEMBL924159 0.84 CA1 (0.36) CA2TSHR
SCHEMBL2750584 0.84 CA1 (0.31) CA2TSHR
SCHEMBL923629 0.82 CA1 (0.38) CA2TSHR
SCHEMBL700472 0.81 TSHR (0.39) CA2TSHRMAPK1
SCHEMBL28276550 0.80 PTGS1 (0.36) CA2
Ammonia Solution, Strong SCHEMBL15061379 0.78 TSHR (0.37) TSHRMAPK1
SCHEMBL126225 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002875-A1 METHOD FOR TREATING AMYLOIDOSIS BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2011-01-06 US claimed
EP-1064013-A4 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIV WASHINGTON (US) 2005-05-11 EP claimed
US-20030108595-A1 Method for treating amyloidosis QUEEN'S UNIVERSITY AT KINGSTON 2003-06-12 US claimed
US-20010048941-A1 Method for treating amyloidosis QUEEN'S UNIVERSITY OF KINGSTON 2001-12-06 US claimed
EP-1064013-A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES University of Washington (US) 2001-01-03 EP claimed
WO-1999045947-A9 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIV WASHINGTON (US) 2000-03-02 WO claimed
WO-1999045947-A1 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIVERSITY OF WASHINGTON (US) 1999-09-16 WO claimed
US-5643562-A ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES QUEEN'S UNIVERSITY OF KINGSTON (CA) 1997-07-01 US claimed
WO-2020017610-A1 PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC COMPOUND 株式会社トクヤマ 2020-01-23 WO disclosed
US-20140155480-A1 Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence WARATAH PHARMACEUTICALS INC. (CA) 2014-06-05 US disclosed
US-20140135403-A1 USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES WARATAH PHARMACEUTICALS INC. (CA) 2014-05-15 US disclosed
EP-2656839-A1 Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases Waratah Pharmaceuticals, Inc. (CA) 2013-10-30 EP disclosed
US-20110105626-A1 USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES MCLAURIN JOANNE 2011-05-05 US disclosed
US-20110002875-A1 METHOD FOR TREATING AMYLOIDOSIS BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2011-01-06 US disclosed
WO-1999045947-A1 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIVERSITY OF WASHINGTON (US) 1999-09-16 WO disclosed
US-5840294-A INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-11-24 US disclosed
US-5728375-A ADMINISTERING A COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE; INHIBITS DEPOSITION BY PREVENTING INTERACTION BETWEEN AN AMYLOIDOGENIC PROTEIN AND A BASEMENT MEMBRANE CONSTITUENT QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-03-17 US disclosed
EP-0814842-A1 METHOD FOR TREATING AMYLOIDOSIS Queen's University at Kingston (CA) 1998-01-07 EP disclosed
US-5643562-A ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES QUEEN'S UNIVERSITY OF KINGSTON (CA) 1997-07-01 US disclosed
WO-1996028187-A1 METHOD FOR TREATING AMYLOIDOSIS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1996-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105626-A1 USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES CDR2, HYPK, HTT CA2 4000/4885TSHR 2538/4885MAPK1 2980/4885
US-20030108595-A1 Method for treating amyloidosis TTR, IAPP, APP CA2 716/4885TSHR 3807/4885MAPK1 2612/4885
US-20010048941-A1 Method for treating amyloidosis TTR, APOB, NEFM CA2 821/4885TSHR 3883/4885MAPK1 2752/4885
US-20140135403-A1 USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES APP, IAPP, TTR CA2 1094/4885TSHR 1412/4885MAPK1 3513/4885
US-20140155480-A1 Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence SCLY, SCO2, SGMS2 CA2 2349/4885TSHR 703/4885MAPK1 4006/4885
US-20110002875-A1 METHOD FOR TREATING AMYLOIDOSIS TTR, IAPP, APP CA2 716/4885TSHR 3807/4885MAPK1 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.